{"id":2785,"date":"2025-02-03T15:39:17","date_gmt":"2025-02-03T12:39:17","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2785"},"modified":"2025-03-07T13:17:20","modified_gmt":"2025-03-07T10:17:20","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201\/","title":{"rendered":"Entrada Therapeutics, ELEVATE-44-201&#039;i Ba\u015flatmak \u0130\u00e7in \u0130ngiltere&#039;den Yetki Ald\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">ENTR-601-44&#039;\u00fcn Faz 1\/2 \u00e7oklu artan doz (MAD) klinik \u00e7al\u0131\u015fmas\u0131 olan ELEVATE-44-201, Birle\u015fik Krall\u0131k \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Ajans\u0131 (MHRA) ve Ara\u015ft\u0131rma Etik Komitesi taraf\u0131ndan Ara\u015ft\u0131rma Ama\u00e7l\u0131 Bir T\u0131bbi \u00dcr\u00fcn\u00fcn Klinik Denemesi i\u00e7in yetkilendirilmi\u015ftir. \u00c7al\u0131\u015fman\u0131n amac\u0131, ekzon 44 atlamaya uygun DMD geninde do\u011frulanm\u0131\u015f bir mutasyonu olan hastalarda Duchenne kas distrofisini (DMD) tedavi etmektir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">ELEVATE-44-201 Klinik \u00c7al\u0131\u015fmas\u0131 Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-44-201, ekzon 44 atlama \u00f6zelli\u011fine sahip ayakta tedavi g\u00f6ren DMD&#039;li hastalarda ENTR-601-44&#039;\u00fcn g\u00fcvenli\u011fini, tolere edilebilirli\u011fini ve etkinli\u011fini de\u011ferlendiren k\u00fcresel, iki par\u00e7al\u0131, randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc bir Faz 1\/2 \u00e7al\u0131\u015fmas\u0131d\u0131r.<\/p>","protected":false},"excerpt":{"rendered":"<p>ELEVATE-44-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[235,49,233,234,141,127,77,48],"class_list":["post-2785","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-44-201","tag-england","tag-entrada","tag-entrada-therapeutics","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-uk"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2785"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2788"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}